AngioDynamics, Inc. (NASDAQ: ANGO) Surpasses Q1 Fiscal 2026 Earnings Expectations
- AngioDynamics, Inc. (NASDAQ:ANGO) reported a narrower-than-expected Q1 fiscal 2026 loss per share of $0.10, beating the Zacks Consensus Estimate.
- The company's revenue reached $75.71 million, marking a 12.2% year-over-year increase, driven by significant growth in its Med Tech segment.
- AngioDynamics raised its fiscal year 2026 sales outlook to $308 million to $313 million, reflecting confidence in continued growth.
AngioDynamics, Inc. (NASDAQ:ANGO), a prominent figure in the medical technology industry, focuses on improving vascular blood flow and expanding cancer treatment options. The company's recent first-quarter fiscal 2026 earnings showcased a narrower-than-expected loss per share of $0.10, surpassing the Zacks Consensus Estimate of a $0.14 loss. This performance indicates an improvement from the previous year's adjusted loss of $0.11 per share.
ANGO's revenue for the quarter was $75.71 million, slightly below the estimated $75.94 million but still represents a 12.2% increase from the previous year. This growth was significantly propelled by a 26.1% increase in its Med Tech segment. Following these results, AngioDynamics' CEO, Jim Clemmer, announced an upward revision of the fiscal year 2026 sales outlook to a range of $308 million to $313 million.
The company's pro-forma adjusted figures, excluding the impact of divested businesses and discontinued products, revealed a GAAP loss per share of $0.26, an improvement from the previous year's loss of $0.32. Despite a negative price-to-earnings (P/E) ratio of -14.44, AngioDynamics maintains a strong liquidity position with a current ratio of 2.29, indicating it has more than twice the amount of current assets compared to its current liabilities.
Following the earnings report, AngioDynamics' stock experienced a significant surge of 10.5% by 11:25 a.m. ET, reflecting investor confidence in the company's performance and future prospects. The company's gross profit margin increased to 55.3%, 90 basis points higher than the previous year, although the GAAP-calculated earnings were lower than the $0.10 per-share adjusted profit.
Despite financial ratio challenges, such as a price-to-sales ratio of 1.53 and an enterprise value to operating cash flow ratio of -49.91, AngioDynamics continues to focus on its core operations. The company's ongoing efforts to improve patient quality of life and expand its medical technology offerings are key drivers of its current momentum and future growth potential.
| Symbol | Price | %chg |
|---|---|---|
| 7741.T | 24225 | 1.53 |
| OMED.JK | 194 | 0.52 |
| 4543.T | 2475 | -0.24 |
| MARK.JK | 715 | 0.7 |
AngioDynamics Inc. (NASDAQ: ANGO) Surpasses Earnings Expectations
- AngioDynamics Inc. (NASDAQ:ANGO) reported an EPS of -$0.11, beating the estimated EPS of -$0.13.
- The company generated $72 million in revenue, indicating a 9.2% increase year-over-year.
- ANGO's financial metrics reveal a negative P/E ratio of -10.89 but a strong current ratio of 2.21, showcasing financial stability.
AngioDynamics Inc. (NASDAQ:ANGO), a leading medical technology company, is renowned for its innovative solutions aimed at improving blood flow, expanding cancer treatment options, and enhancing patient quality of life. Operating within the Zacks Medical - Instruments industry, AngioDynamics is committed to transformative healthcare.
On April 2, 2025, ANGO unveiled its earnings, showcasing an earnings per share (EPS) of -$0.11, which surpassed the estimated EPS of -$0.13. This performance aligns with the company's history of exceeding expectations. In the preceding quarter, ANGO reported an adjusted EPS of $0.03, significantly outperforming the Zacks Consensus Estimate of a $0.13 loss per share, resulting in an impressive earnings surprise of 123.08%.
The company reported revenue of $72 million, slightly below the forecasted $74.2 million. Nevertheless, this figure represents a 9.2% increase compared to the previous year, surpassing the expected $70.3 million. Despite a minor decline from the $75.18 million reported in the same quarter the previous year, ANGO has consistently beaten consensus revenue estimates in three of the last four quarters.
ANGO's financial metrics highlight some challenges, with a negative price-to-earnings (P/E) ratio of -10.89 and an earnings yield of approximately -9.18%. These figures indicate negative earnings, yet the price-to-sales ratio of 1.58 suggests that investors are willing to pay $1.58 for every dollar of the company's sales. Moreover, the enterprise value to sales ratio of 1.42 offers insights into the company's valuation relative to its sales.
The company's current ratio of approximately 2.21 demonstrates a robust ability to cover short-term liabilities with short-term assets. This financial stability, coupled with ANGO's consistent track record of surpassing earnings and revenue estimates, has contributed to an optimistic annual guidance for AngioDynamics.
AngioDynamics Inc. (NASDAQ: ANGO) Surpasses Earnings Expectations
- AngioDynamics Inc. (NASDAQ:ANGO) reported an EPS of -$0.11, beating the estimated EPS of -$0.13.
- The company generated $72 million in revenue, indicating a 9.2% increase year-over-year.
- ANGO's financial metrics reveal a negative P/E ratio of -10.89 but a strong current ratio of 2.21, showcasing financial stability.
AngioDynamics Inc. (NASDAQ:ANGO), a leading medical technology company, is renowned for its innovative solutions aimed at improving blood flow, expanding cancer treatment options, and enhancing patient quality of life. Operating within the Zacks Medical - Instruments industry, AngioDynamics is committed to transformative healthcare.
On April 2, 2025, ANGO unveiled its earnings, showcasing an earnings per share (EPS) of -$0.11, which surpassed the estimated EPS of -$0.13. This performance aligns with the company's history of exceeding expectations. In the preceding quarter, ANGO reported an adjusted EPS of $0.03, significantly outperforming the Zacks Consensus Estimate of a $0.13 loss per share, resulting in an impressive earnings surprise of 123.08%.
The company reported revenue of $72 million, slightly below the forecasted $74.2 million. Nevertheless, this figure represents a 9.2% increase compared to the previous year, surpassing the expected $70.3 million. Despite a minor decline from the $75.18 million reported in the same quarter the previous year, ANGO has consistently beaten consensus revenue estimates in three of the last four quarters.
ANGO's financial metrics highlight some challenges, with a negative price-to-earnings (P/E) ratio of -10.89 and an earnings yield of approximately -9.18%. These figures indicate negative earnings, yet the price-to-sales ratio of 1.58 suggests that investors are willing to pay $1.58 for every dollar of the company's sales. Moreover, the enterprise value to sales ratio of 1.42 offers insights into the company's valuation relative to its sales.
The company's current ratio of approximately 2.21 demonstrates a robust ability to cover short-term liabilities with short-term assets. This financial stability, coupled with ANGO's consistent track record of surpassing earnings and revenue estimates, has contributed to an optimistic annual guidance for AngioDynamics.
AngioDynamics, Inc. (NASDAQ: ANGO) Earnings Report Highlights
- AngioDynamics reported a Q2 2025 EPS of -$0.26, which was lower than the estimated -$0.11.
- The company's revenue reached $72.8 million, indicating strong sales performance despite financial challenges.
- Med Tech division saw a 25% increase in revenue, driven by key products and FDA clearance of NanoKnife for prostate cancer treatment.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company that specializes in the development and sale of innovative medical devices. The company operates in the healthcare sector, focusing on vascular access, peripheral vascular disease, and oncology. AngioDynamics competes with other medical technology firms, striving to deliver advanced solutions for patient care.
On January 8, 2025, AngioDynamics reported an earnings per share (EPS) of -$0.26, which was lower than the estimated -$0.11. However, the company generated a revenue of approximately $72.8 million, surpassing the estimated $70.6 million. This indicates that while the company faced challenges in profitability, it managed to exceed revenue expectations.
The Med Tech division was a standout performer, achieving a 25% increase in revenue. This growth was driven by the strong market performance and acceptance of key products such as Auryon, AlphaVac, and AngioVac. Additionally, the NanoKnife received FDA clearance and showed promising results in clinical trials for prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.
Despite a negative price-to-earnings (P/E) ratio of -2.36 and a negative earnings yield of -42.44%, AngioDynamics' stock surged by 35% following the earnings report. The company's current ratio of nearly 1.98 reflects its ability to cover short-term liabilities with its short-term assets, indicating a stable liquidity position. However, the enterprise value to operating cash flow ratio of -20.24 highlights ongoing challenges in generating positive cash flow from operations.
AngioDynamics, Inc. (NASDAQ: ANGO) Earnings Report Highlights
- AngioDynamics reported a Q2 2025 EPS of -$0.26, which was lower than the estimated -$0.11.
- The company's revenue reached $72.8 million, indicating strong sales performance despite financial challenges.
- Med Tech division saw a 25% increase in revenue, driven by key products and FDA clearance of NanoKnife for prostate cancer treatment.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company that specializes in the development and sale of innovative medical devices. The company operates in the healthcare sector, focusing on vascular access, peripheral vascular disease, and oncology. AngioDynamics competes with other medical technology firms, striving to deliver advanced solutions for patient care.
On January 8, 2025, AngioDynamics reported an earnings per share (EPS) of -$0.26, which was lower than the estimated -$0.11. However, the company generated a revenue of approximately $72.8 million, surpassing the estimated $70.6 million. This indicates that while the company faced challenges in profitability, it managed to exceed revenue expectations.
The Med Tech division was a standout performer, achieving a 25% increase in revenue. This growth was driven by the strong market performance and acceptance of key products such as Auryon, AlphaVac, and AngioVac. Additionally, the NanoKnife received FDA clearance and showed promising results in clinical trials for prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.
Despite a negative price-to-earnings (P/E) ratio of -2.36 and a negative earnings yield of -42.44%, AngioDynamics' stock surged by 35% following the earnings report. The company's current ratio of nearly 1.98 reflects its ability to cover short-term liabilities with its short-term assets, indicating a stable liquidity position. However, the enterprise value to operating cash flow ratio of -20.24 highlights ongoing challenges in generating positive cash flow from operations.
